Evidence map›Paper›PMID 33889275›Full record

ReviewWorld journal of gastrointestinal oncology2021

Nanotechnology and pancreatic cancer management: State of the art and further perspectives.

Damiano Caputo, Daniela Pozzi, Tommaso Farolfi, Roberto Passa, Roberto Coppola, Giulio Caracciolo

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastrointestinal oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Hot topics in pancreatic cancer management.World journal of gastrointestinal surgery · 2023
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Damiano CaputoDepartment of General Surgery, University Campus Bio-Medico di Roma, Rome 00128, Italy. d.caputo@unicampus.it.
Daniela PozziDepartment of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy.
Tommaso FarolfiDepartment of General Surgery, University Campus Bio-Medico di Roma, Rome 00128, Italy.
Roberto PassaDepartment of General Surgery, University Campus Bio-Medico di Roma, Rome 00128, Italy.
Roberto CoppolaDepartment of General Surgery, University Campus Bio-Medico di Roma, Rome 00128, Italy.
Giulio CaraccioloDepartment of Molecular Medicine, Sapienza University of Rome, Rome 00161, Italy.
Università Campus Bio-Medico · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) represents a leading cause of cancer death and is often diagnosticated too late to allow adequate treatments. Lots of biomarkers have been discovered in lasts years but, to date, there is a lack of low-cost and non-invasive tools for PDAC early detection. Nonetheless, drugs commonly used in PDAC treatment do not allow achieving long-term satisfying results. Nanotechnology is gaining importance in both PDAC early detection and treatment. The main implications of nanotechnology in cancer diagnosis lay in the ability that nanoparticles have on concentrate the alteration in human proteome caused by cancer. Nanoparticle-enabled blood tests have been demonstrated to reach high rate of sensitivity (up to 85%) and specificity (up to 100%). In the field of cancer therapy nanoparticles can be used as nanocarriers able to reach specific tumour's cells and selectively release the drug they contain into them. A literature review was carried out with the aim to assess the state of the art and highlight the future perspectives of nanotechnology in PDAC early detection and therapy.

Indexed as

BiomarkersEarly detectionNanoparticlesNanotechnologyPancreatic ductal adenocarcinomaProtein corona

Identifiers

PMID33889275
PMCPMC8040067
OpenAlexW3153620455

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.